Outlook Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Outlook Therapeutics generated cash of -$42,973,398, which is more than the previous year. Cash used in financing activities reached the amount of $48,968,568 last year. Net change in cash is therefore $5,995,170.
Cash Flow
| 2014 | -7.02M | -2.36M | 11.47M |
|---|---|---|---|
| 2015 | -27.47M | -8.80M | 43.00M |
| 2016 | -45.48M | -1.09M | 39.86M |
| 2017 | -15.50M | -292.08K | 16.63M |
| 2018 | -33.03M | -2.78M | 34.35M |
| 2019 | -32.28M | -437.30K | 39.02M |
| 2020 | -31.79M | -900K | 37.21M |
| 2021 | -54.25M | 0 | 56.19M |
| 2022 | -56.67M | 0 | 59.59M |
| 2023 | -42.97M | 0 | 48.96M |
OTLK Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 17.39M | 14.47M | 12.53M | 8.01M | 1.71M | 3.18M | 2.35M | 9.07M | 2.34M | 262.40K |
Operating activities | ||||||||||
Net income | -58.98M | -66.05M | -53.16M | -35.23M | -34.52M | -46.11M | -38.84M | -53.32M | -48.66M | -13.73M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 44.18K | 204.69K | 262.14K | 554.06K | 3.36M | -3.05M | 2.69M | 2.39M | 1.82M | 878.47K |
Stock-based compensation expense | 5.54M | 7.71M | 4.88M | 2.80M | 1.31M | 0 | 8.57M | 12.45M | 11.17M | 3.95M |
| Deferred income tax benefit | 5.54M | 7.71M | 4.88M | 2.80M | 1.31M | 0 | 8.57M | 12.45M | 11.17M | 3.95M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20K | -20K | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -221.36K | 1.08M | 0 |
Accounts payable | 3.08M | 1.29M | -198.46K | -1.48M | -1.33M | -6.71M | 5.72M | -5.32M | 6.58M | -96.40K |
Cash generated by operating activities | -42.97M | -56.67M | -54.25M | -31.79M | -32.28M | -33.03M | -15.50M | -45.48M | -27.47M | -7.02M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | -900K | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -2 | 0 | 0 | 0 | -437.30K | -2.78M | -292.08K | -1.09M | -8.80M | -2.36M |
Acquisitions Net | 0 | 0 | 0 | -900K | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 0 | 0 | -900K | -437.30K | -2.78M | -292.08K | -1.09M | -8.80M | -2.36M |
Financing activities | ||||||||||
Common Stock Issued | 30.02M | 62.30M | 46.30M | 35.43M | 45.96M | 36.43M | 1.60M | 53.21M | 41.24M | 11.04M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | -16.98B | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 166.13B | 0 | -1.08M | 0 | -71 | -226.00K | -4.12M |
Repayments of term debt | 19.76M | -2.31M | -3.69M | -263.27K | -6.94M | -990.64K | 11.33M | -13.54M | 1.57M | -4.07M |
Cash used in financing activities | 48.96M | 59.59M | 56.19M | 37.21M | 39.02M | 34.35M | 16.63M | 39.86M | 43.00M | 11.47M |
Net Change In Cash | 5.99M | 2.91M | 1.94M | 4.52M | 6.29M | -1.46M | 833.63K | -6.71M | 6.72M | 2.08M |
Cash at end of period | 23.39M | 17.39M | 14.47M | 12.53M | 8.01M | 1.71M | 3.18M | 2.35M | 9.07M | 2.34M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |